An exosome-based liquid biopsy to predict molecular residual disease for the identification of high-risk patients with stage II-III colorectal cancer: the CLEAR study - PubMed
3 hours ago
- #Liquid Biopsy
- #Colorectal Cancer
- #Exosomal miRNA
- Exosome-based liquid biopsy to predict molecular residual disease in stage II-III colorectal cancer.
- Study named CLEAR focuses on identifying high-risk patients for better treatment strategies.
- Keywords include Adjuvant chemotherapy, Exosomal miRNA, Liquid biopsy, Molecular residual disease, and Stage II-III CRC.
- Ethics approval obtained from Tokyo Medical and Dental University and Hospital del Mar.
- No competing interests declared by the authors.
- References include studies on adjuvant therapy, molecular residual disease, and chemotherapy duration for colorectal cancer.